Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04338841
Other study ID # 2020-A00831-38
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 9, 2020
Est. completion date June 17, 2020

Study information

Verified date April 2020
Source University Hospital, Angers
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 pandemic has developed worldwide in less than 4 months. The clinical presentations are variable widely, ranging from simple rhinitis to major lung damage that can lead to death.

In many countries involved in the ongoing health disaster due to SARS-CoV-2 infection, hospital are overloaded. In this context, the decision to hospitalize or to manage COVID-19 patients at home is crucial and defining reliable and consensual criteria is a major issue.

HOME-CoV study is a multicentre quasi-experimental interventional study, before and after implementation of a help-decision making rule (HOME-CoV rule), developed via the Delphi method.

Our main hypothesis is that a strategy based on the consensual HOME-CoV rule compared to current practice is at least as safe as regards the 7-day-rate of adverse events (safety criterion) and more effective as regards the rate of patients eventually managed as outpatients (efficacy criterion).


Description:

Definition of HOME-CoV rule:

The Delphi method is used to reach a consensus of a large panel of experts and to define an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making : the HOME-CoV rule.

The impact of the rule implementation is evaluated in a before and after study:

- before period: observational assessment of current practices

- implementation period : educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.

- after period : observational assessment of practices

In each period, patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.

A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.


Recruitment information / eligibility

Status Completed
Enrollment 3133
Est. completion date June 17, 2020
Est. primary completion date June 17, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patient (= 18 years old)

- Admitted for COVID-19 infection confirmed by a positive SARS-CoV2 RT-PCR or considered probable by the physician in charge of the patient.

- Not requiring care in intensive care unit or resuscitation unit or

- No subject of a limitation decision of active therapies,

- Free informed express consent to participate in the study orally given or signed by the patient according to local legislation,

- Insurance cover according to local legislation;

Exclusion Criteria:

- Patient whose main diagnostic hypothesis in the emergency room is not a SARS-CoV-2 infection but another differential diagnosis,

- Patient admitted to the emergency room for 18 hours or more,

- Patient whose follow-up on D28 is impossible, whatever the reason,

- Patient with a poor understanding of the French language,

- Patient already included in the study,

- Person deprived of their liberty by judicial or administrative decision,

- Person under psychiatric care under duress,

- Person subject to a legal protection measure,

- Person unable to express consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HOME-CoV rule implementation
HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts. Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.

Locations

Country Name City State
Belgium Clinique Universitaire Saint-Luc Bruxelles
Belgium CHU de Liège Liege
France Ch Argenteuil Argenteuil
France CH Cholet Cholet
France CHU Clermont Ferrand Clermont Ferrand
France Ch Colmar Colmar
France CH Alpes Lemant Contamine-sur-Arve
France CHU Dijon Dijon
France CH Le Mans Le Mans
France CH Libourne Libourne
France CH Limoges Limoges
France Ch Longjumeau Longjumeau
France Chu Montpellier Montpellier
France Centre Hospitalier Universitaire de Nantes Nantes
France CH Niort Niort
France Hôpital Bichat Paris
France Hôpital Lariboisière Paris
France Hopital Paris Saint Joseph Paris
France Hopital Saint Antoine Paris
France CHU de Poitiers Poitiers
France CH Reims Reims
France Ch Remiremont Remiremont
France Chu Rennes Rennes
France CHU de Rouen Rouen
France CHU de St Etienne Saint Etienne
France CH de Saint-Brieuc Saint-Brieuc
France Ch Troyes Troyes
France CH VICHY Vichy
Monaco CH Princesse Grace Monaco

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Countries where clinical trial is conducted

Belgium,  France,  Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary the composite rate of adverse outcomes Adverse outcomes include intubation with mechanical ventilation requirement and death (Stage = 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 7 days after inclusion. day 7
Primary The rate of hospitalization The rate of patients hospitalized after admission to the emergency room including patients discharged home more than 24 hours after admission.
It will be analyzed in a hierarchical approach, only if first primary objective is positive i.e. non-inferiority of HOME-CoV strategy versus current practice on the rate of adverse outcomes.
24 hours
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04383899 - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Completed NCT04532632 - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04413435 - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT04510493 - Canakinumab in Patients With COVID-19 and Type 2 Diabetes Phase 3
Active, not recruiting NCT04587219 - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older Phase 2
Withdrawn NCT05430958 - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers Phase 1
Completed NCT04596579 - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Terminated NCT04442230 - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Phase 2
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3